GlassScriptPhysician profile
Rajesh J Patel
NPI 1265492763
$50,576.39
in general payments reported to CMS, 2019-2025
40 companies · $1,728 in 2025
The $1,728 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $21K · 2021: $2,885 · 2022: $1,455 · 2023: $4,573 · 2024: $1,598 · 2025: $1,728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,750 · Travel and Lodging: $3,069 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,749.98 |
| Travel and Lodging | $3,069.29 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $20,598.01 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $9,127.30 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $8,497.51 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Intuitive Surgical, INC. | $3,412.24 | 2022-2023 | Da Vinci Surgical System |
| Actelion Pharmaceuticals US, INC. | $1,335.28 | 2019-2025 | Opsumit, Uptravi |
| Insmed, INC. | $1,053.33 | 2019-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $841.06 | 2019-2025 | Dupixent |
| Covidien LP | $749.21 | 2019 | |
| Mylan Specialty L.P. | $681.39 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $478.60 | 2019-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $352.14 | 2020-2025 | Aralast |
| United Therapeutics Corporation | $307.57 | 2019-2025 | Tyvaso, Tyvaso |
| Jazz Pharmaceuticals INC. | $303.14 | 2019-2021 | |
| Electromed, INC. | $301.95 | 2021-2025 | Smartvest |
| Genzyme Corporation | $262.95 | 2019-2023 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $249.97 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $242.93 | 2019-2024 | |
| Philips North America LLC | $206.52 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $203.07 | 2019-2020 | |
| Viatris Specialty LLC | $171.11 | 2025 | Yupelri |
| Ani Pharmaceuticals, INC. | $155.53 | 2024-2025 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $152.35 | 2023-2025 | Sunosi |
| Galvanize Therapeutics, INC | $141.44 | 2025 | Aliya System |
| Nabriva Therapeutics, Plc | $116.16 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $96.88 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.61 | 2019-2025 | |
| Circassia INC. | $75.38 | 2019-2020 | |
| Tactile Systems Technology INC | $63.97 | 2024 | Flexitouch Plus, Entre Plus |
| Pulmonx Corporation | $51.40 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Masimo Corporation | $44.25 | 2019 | |
| Lilly USA, LLC | $39.62 | 2025 | Zepbound |
| Mallinckrodt Hospital Products INC. | $31.96 | 2020 | |
| Verona Pharma, INC. | $31.22 | 2025 | Ohtuvayre |
| Boston Scientific Corporation | $21.45 | 2024 | Embold Fibered |
| Amgen INC. | $19.79 | 2024 | Tezspire |
| Merck Sharp & Dohme LLC | $18.86 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.88 | 2019 | |
| Resmed Corp | $15.57 | 2019 | |
| Breas Medical, INC. | $15.54 | 2024 | Vivo 45 Ls |
| Eisai INC. | $14.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.